Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $194K invested in Global X China Biotech Innovation ETF in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
53% more capital invested
Capital invested by funds: $127K → $194K (+$67.4K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$53.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
-$3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$228 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $180K | +$53.6K | +5,864 | +44% |
|
|
2
UBS Group
Zurich,
Switzerland
| $14.5K | -$228 | -25 | -2% |
|
|
BBPWM
3
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| – | -$3K | -300 | Closed |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | +$9 | +1 | New |
|
CHB Hedge Fund Activity: Q4 2022 in Review
3 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q4 2022, worth a combined $194K — up 53% from $127K a quarter earlier.
Fund positioning in CHB was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, adding an estimated $53.6K. The largest seller was Blue Bell Private Wealth Management, exiting entirely with an estimated $3K sold.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $194K of Global X China Biotech Innovation ETF stock for Q4 2022, up 53% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q4 2022 and 1 closed out, a net change of 0 holders.
- The largest Global X China Biotech Innovation ETF buyer in Q4 2022 was Jane Street, an estimated $53.6K added.
- The largest Global X China Biotech Innovation ETF seller in Q4 2022 was Blue Bell Private Wealth Management, an estimated $3K sold.
Based on aggregated 13F filings for Q4 2022.